Omnicell President Sells 6,753 Shares
Key Points
The disposal comprised 6,753 shares representing a total transaction value of ~$250,000.
The transaction reduced the insider's direct equity holdings by 4%.
Activity was split between a Rule 10b5-1 plan sale and 3,670 shares withheld for tax obligations related to the vesting of restricted stock units.
The execution occurred following a 14% one-year stock return as of the August 17, 2026 transaction date.
President & COO Nnamdi Njoku reported a sale of 6,753 shares of Omnicell, Inc. (NASDAQ:OMCL) at ~$37.09 per share on August 15, 2026, and August 17, 2026, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | ~$250,000 |
| Shares sold (direct) | 6,753 |
| Post-transaction shares (directly held) | ~161,000 |
| Post-transaction value | $5.81 million |
Transaction value based on SEC Form 4 weighted average sale price ($37.09); post-transaction value based on August 17, 2026, market close ($36.03).
Key questions
- To what extent was the sale discretionary?
Approximately 54% of the disposal involved non-discretionary tax withholding to cover obligations arising from equity vesting, while the remaining 3,083 shares were sold under a Rule 10b5-1 trading plan. - When was the trading plan established?
The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by the President & COO on February 9, 2026, which allows for pre-scheduled transactions to avoid potential conflicts of interest. - What is the insider's remaining interest in the company?
Nnamdi Njoku maintains a direct position of 161,223.5647 shares of common stock, representing a 0.35% ownership stake in the firm. - How has the stock performed leading up to this transaction?
Shares of the healthcare technology company were priced at $36.03 as of the August 17, 2026 market close, contributing to a 14% return over the preceding 12-month period.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-17) | $36.03 |
| Market Capitalization | $1.6 billion |
| Revenue (TTM) | $1.2 billion |
| Net Income (TTM) | $39 million |
Company Snapshot
- Omnicell provides healthcare technology solutions, including automated medication dispensing systems (Titan XT), point-of-care clinical workflow solutions, and central pharmacy automation services, generating revenue through software licensing, equipment sales, and managed services.
- The company operates on a recurring revenue model, delivering integrated medication management and pharmacy automation platforms to hospitals and health systems, with revenue derived from equipment sales, software subscriptions, and ongoing managed services.
- Omnicell serves hospital systems, health networks, and pharmacy operations across the United States and international markets, targeting healthcare providers seeking to optimize medication dispensing workflows and reduce operational costs.
Omnicell is a healthcare technology provider with a $1.6 billion market capitalization, generating $1.2 billion in TTM revenue through its portfolio of automated medication management and pharmacy dispensing solutions.
The company operates at scale, with 3,525 employees, and has demonstrated strong market performance, achieving a 13.7% one-year stock appreciation, positioning itself as a key player in healthcare automation and clinical workflow optimization.
What this transaction means for investors
This sale shouldn't concern investors. The sale was executed under a pre-adopted trading plan and to satisfy tax obligations. Moreover, the executive retained about 161,223 shares, representing the vast majority of the stake.
Importantly, the sale comes after another year of growth for Omnicell, with TTM revenue up 8.5% year over year. There doesn't appear to be anything out of the ordinary with the company's financial performance.
Investors and analysts remain high on the company's growth prospects, as reflected by its high price-to-earnings ratio of 43. Analysts expect earnings to grow at an annualized rate of nearly 30% in the coming years. If the company meets those estimates, the stock could deliver excellent returns to shareholders.
John Ballard has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.